PMID: 2992561Jul 1, 1985Paper

The effect of captopril on the reflex control heart rate: possible mechanisms

British Journal of Clinical Pharmacology
A A AjayiJ L Reid


Angiotensin converting enzyme inhibitors reduce blood pressure without reflex tachycardia, possibly as a result of enhanced hypothesis that this results from the removal of the parasympathetic activity. We examined the vagolytic action of angiotensin II or alternatively by acetylcholinesterase inhibition. Both captopril and [Sar1ala8] angiotensin II, (saralasin), caused modest falls in blood pressure, without increasing heart rate in normotensive subjects. Captopril and saralasin significantly attenuated the vagally mediated heart rate slowing after facial immersion in water. There was a close correlation between the effects produced by captopril and saralasin on the diving reflex. Infusion of subpressor doses of angiotensin II, reversed the hypotensive effect of captopril and returned the bradycardia after facial immersion to placebo level. In vitro neither captopril nor enalapril or lisinopril affected bovine erythrocyte acetylcholinesterase activity. The parasympathetic effect of angiotensin converting enzyme inhibitors appear to reflect a direct consequence of the removal of angiotensin II.


Jan 1, 1980·Neuroscience·I W ChubbG H White
May 1, 1982·Journal of Cardiovascular Pharmacology·A N ShepherdJ L Reid
Jan 1, 1982·Clinical and Experimental Hypertension. Part A, Theory and Practice·A P NiarchosJ H Laragh
Dec 1, 1982·British Journal of Clinical Pharmacology·A SturaniP Zucchelli
Jan 1, 1982·Clinical Science·F Bellavere, D J Ewing
Jan 1, 1982·British Journal of Pharmacology·E K Potter


Jan 1, 1986·European Journal of Clinical Pharmacology·A A AjayiJ L Reid
Feb 1, 1990·Cardiovascular Drugs and Therapy·N Sharpe
Feb 1, 1997·Journal of Hepatology·J F DillonP C Hayes
Nov 17, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Kashif HanifRituraj Konwar
Feb 1, 1991·British Journal of Clinical Pharmacology·S Capewell, A Capewell
Jan 1, 1990·Fundamental & Clinical Pharmacology·J L GérardJ F Giudicelli
Jan 24, 1998·Clinical and Experimental Hypertension : CHE·R H BeckerK J Schulze
Jan 1, 1989·Journal of Toxicology. Clinical Toxicology·H A SpillerS Muir
Jan 1, 1991·Clinical and Experimental Hypertension. Part A, Theory and Practice·D T PalsM N Brunden
Mar 1, 1994·Journal of Physiology and Pharmacology : an Official Journal of the Polish Physiological Society·R G AnderssonK Persson
May 30, 1998·The American Journal of Cardiology·E PinarM Valdés
Nov 30, 1999·Anesthesia and Analgesia·P ColsonP Coriat
Jun 18, 2010·Canadian Journal of Physiology and Pharmacology·Anita MehtaRamesh Goyal
Apr 1, 1986·British Journal of Clinical Pharmacology·A A AjayiJ L Reid
Jan 1, 1989·British Journal of Clinical Pharmacology·H L ElliottJ L Reid
Mar 1, 1986·British Journal of Clinical Pharmacology·A A Ajayi, J L Reid
Mar 1, 1988·British Journal of Clinical Pharmacology·G B KondoweD W Harron
Feb 1, 1987·British Journal of Clinical Pharmacology·J WebsterJ C Petrie
May 13, 1998·Circulation·N J Brown, D E Vaughan
Jan 1, 1988·Acta Medica Scandinavica·J AhlnerJ Ohlsson
Mar 1, 1986·British Journal of Clinical Pharmacology·J F Giudicelli, A Berdeaux
Dec 8, 1988·The New England Journal of Medicine·G H Williams

Related Concepts

Related Feeds


Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.